MediPal Holdings (7459) Q4 2025 earnings summary

Executive summary

• Consolidated net sales for FY2024 reached ¥3,671.3 billion, up 3.2% year-over-year, with operating profit at ¥55.6 billion, up 17.5%.

• All business segments achieved net sales growth; operating profit hit record levels, aided by reduced SG&A from delayed investments.

• Profit attributable to owners declined 2.9% to ¥40.2 billion due to higher income taxes despite increased extraordinary income.

• Strategic investments included acquisitions of PreMedica Inc., Aculys Pharma, and expansion in rare disease drug development.

• Share buyback and cancellation were resolved to improve capital efficiency, with further increases and buybacks planned.

Financial highlights

• Net sales: ¥3,671.3 billion (+3.2% YoY); operating profit: ¥55.6 billion (+17.5% YoY); adjusted operating profit: ¥59.0 billion (+7.0% YoY).

• Ordinary profit: ¥65.2 billion (+1.1% YoY); profit attributable to owners: ¥40.2 billion (−2.9% YoY) due to lower equity method earnings.

• Gross profit increased 3.7% to ¥255.8 billion; gross margin improved to 6.97%.

• Cash and cash equivalents at year-end were ¥259.3 billion, up ¥31.3 billion year-over-year.

• Annual dividend per share was ¥62, with a payout ratio of 32.1%.

Outlook and guidance

• FY2025/2026 forecast: net sales ¥3,785.0 billion (+3.1%), operating profit ¥52.0 billion, adjusted operating profit ¥60.7 billion.

• Profit attributable to owners forecast at ¥34.5 billion (−14.3% YoY); ordinary profit expected to rise 5.7% to ¥69.0 billion.

• Annual dividend forecast raised to ¥64 per share; up to ¥8 billion in share buybacks planned.

• Guidance reflects anticipated higher logistics costs, market uncertainties, and continued investment in growth strategies.